Search Result
Results for "
eosinophils
" in MedChemExpress (MCE) Product Catalog:
5
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-W105101
-
-
-
- HY-101173
-
|
VUF 8325 dihydrobromide; SKF 91105 dihydrobromide
|
Histamine Receptor
|
Neurological Disease
|
|
Imetit dihydrobromide (VUF 8325 dihydrobromide) is a high affinity and potent agonist of histamine H3 and H4 receptors, with Ki values of 0.3 and 2.7 nM, respectively. Imetit mimics histamine effect in triggering a shape change in eosinophils (EC50=25 nM) .
|
-
-
- HY-B1121
-
-
-
- HY-106215
-
|
BNP 166; Etiprednol dichloroacetate
|
TNF Receptor
|
Inflammation/Immunology
|
|
Etiprednol dicloacetate (BNP 166) is an anti-inflammatory agent. Etiprednol dicloacetate inhibits eosinophil accumulation. Etiprednol dicloacetate can be used in the research of inflammatory airway diseases, such as asthma .
|
-
-
- HY-137493
-
|
14,15-LTD4; Eoxin D4
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
14,15-Leukotriene D4 (14,15-LTD4) is a leukotriene that producted by eosinophils with Arachidonic acid (HY-109590), and through the 15-lipoxygenase-1 pathway .
|
-
-
- HY-120629
-
|
|
CCR
|
Inflammation/Immunology
|
|
BMS-639623 is a potent and orally activeCCR3 antagonist with an IC50 of 0.3 nM. BMS-639623 picomolar inhibition potency against eosinophil chemotaxis (IC50=38 pM). BMS-639623 can be used for the research of asthma .
|
-
-
- HY-137308
-
|
15R-PGD2
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
15(R)-Prostaglandin D2 is a potential prostatic hormone DP(2) receptor (Prostaglandin Receptor) agonist with anti-inflammatory activity. 15(R)-Prostaglandin D2 increases actin polymerization in human eosinophils and increases cAMP levels in platelets .
|
-
-
- HY-P99846
-
|
QAX576
|
Interleukin Related
|
Inflammation/Immunology
|
|
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
|
-
-
- HY-155819
-
|
|
mAChR
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
M3/PDE4 modulator-1 (compound 10f) is a bifunctional molecule that is an M3 mAChR antagonist and a PDE4 inhibitor. M3/PDE4 modulator-1 (10-1000 nM/kg; iv) reduces cysteine eosinophil influx in the OVA rat model .
|
-
-
- HY-B1121A
-
-
-
- HY-19969
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
YM-90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R).YM-90709 potently inhibits the binding of [ 125I]-IL-5 to IL-5R on human peripheral eosinophils and eosinophilic HL-60 clone 15 cells with IC50 values of 1.0 and 0.57 μM .
|
-
-
- HY-14277A
-
|
R 50547 hydrochloride
|
Histamine Receptor
Neurotensin Receptor
Integrin
|
Inflammation/Immunology
|
|
Levocabastine (R 50547) hydrochloride is a potent and selective histamine H1-receptor antagonist. Levocabastine hydrochloride is also a selective, high affinity neurotensin receptor subtype 2 (NTR2) antagonist, with a Ki of 17 nM for mNTR2. Levocabastine hydrochloride can act as a VLA-4 antagonist, interferes with conjunctival eosinophil infiltration in allergic conjunctivitis (AC) .
|
-
-
- HY-14277
-
|
R 50547
|
Histamine Receptor
Neurotensin Receptor
Integrin
|
Inflammation/Immunology
|
|
Levocabastine (R 50547) is a potent and selective histamine H1-receptor antagonist. Levocabastine hydrochloride is also a selective, high affinity neurotensin receptor subtype 2 (NTR2) antagonist, with a Ki of 17 nM for mNTR2. Levocabastine can act as a VLA-4 antagonist, interferes with conjunctival eosinophil infiltration in allergic conjunctivitis (AC) .
|
-
-
- HY-P990094
-
|
CSL311
|
c-Fms
|
Inflammation/Immunology
|
|
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research .
|
-
-
- HY-B1121AR
-
|
|
Glucocorticoid Receptor
Apoptosis
|
Inflammation/Immunology
Endocrinology
|
|
Flunisolide (hemihydrate) (Standard) is the analytical standard of Flunisolide (hemihydrate). This product is intended for research and analytical applications. Flunisolide hemihydrate is a corticosteroid, which is an orally active glucocorticoid receptor activator with anti-inflammatory activity. Flunisolide hemihydrate can induce eosinophil apoptosis, and is used for the research of asthma or rhinitis, and inflammation .
|
-
-
- HY-14277AR
-
|
|
Histamine Receptor
Neurotensin Receptor
Integrin
|
Inflammation/Immunology
|
|
Levocabastine (hydrochloride) (Standard) is the analytical standard of Levocabastine (hydrochloride). This product is intended for research and analytical applications. Levocabastine (R 50547) hydrochloride is a potent and selective histamine H1-receptor antagonist. Levocabastine hydrochloride is also a selective, high affinity neurotensin receptor subtype 2 (NTR2) antagonist, with a Ki of 17 nM for mNTR2. Levocabastine hydrochloride can act as a VLA-4 antagonist, interferes with conjunctival eosinophil infiltration in allergic conjunctivitis (AC) .
|
-
-
- HY-103158
-
|
|
Lipoxygenase
|
Others
|
|
BW B70C is a potent, selective and orally activearachidonic acid 5-lipoxygenase inhibitor. BW B70C inhibits both acute and allergic bronchoconstriction and late-phase eosinophil accumulation subsequent to allergen inhalation in guinea-pigs. BW B70C prevents leukotriene C4 synthesis and reduces leucocyte migration to the airways lumen as well as albumin microvascular leakage. BW B70C has the potential for the research of anti-asthma agent .
|
-
-
- HY-P99371
-
|
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
-
-
- HY-P9945
-
|
SB 240563
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
-
-
- HY-123532
-
|
VUF6002
|
Histamine Receptor
|
Neurological Disease
|
|
JNJ10191584 (VUF6002) is an orally active and selective histamine H4 receptor antagonist with a Ki value of 26 nM. JNJ10191584 shows 540-fold selectivity to H4 receptor over H3 receptor with a Ki value of 14.1 μM. JNJ10191584 inhibits chemotaxis of eosinophils and mast cells with IC50 values of 530 nM and 138 nM, respectively .
|
-
-
- HY-P9945A
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
-
-
- HY-117854
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
SB 201146 is an LTB4 receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma .
|
-
-
- HY-107558
-
|
VUF6002 maleate
|
Histamine Receptor
|
Neurological Disease
|
|
JNJ10191584 (VUF6002) maleate (compound 40) is an orally active and selective histamine H4 receptor antagonist with a Ki value of 26 nM. JNJ10191584 maleate shows 540-fold selectivity to H4 receptor over the H3 receptor with a Ki value of 14.1 μM. JNJ10191584 maleate inhibits chemotaxis of eosinophils and mast cells with IC50 values of 530 nM and 138 nM, respectively .
|
-
-
- HY-123862
-
|
|
PI3K
Lipase
G Protein-coupled Receptor Kinase (GRK)
|
Inflammation/Immunology
|
|
LAS195319 is an orally active and potent inhibitor against PI3Kδ with an IC50 value of 0.5 nM. LAS195319 is also a highly selective inhibitor against an extensive panel of proteins, lipid kinases and GPCRs. LAS195319 causes an inhibition of neutrophil and eosinophil infiltration. LAS195319 is promising for research of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) .
|
-
-
- HY-159927
-
|
|
CCR
|
Inflammation/Immunology
|
|
TAK-661 is a inhibitor of eosinophil chemotaxis. TAK-661 significantly reduces the bronchoconstriction during the late phase, along with the inhibition of eosinophilia in bronchoalveolar lavage (BAL) and the eosinophil infiltration into the airway wall .
|
-
-
- HY-114732
-
|
|
Adrenergic Receptor
|
Others
|
|
Procaterol is an oral selective β2 adrenergic receptor agonist. Procaterol inhibits eosinophil migration and the release of eosinophil chemotactic factor from BEAS-2B cells through a cyclic AMP-dependent mechanism. Procaterol has a large dose difference existing between the bronchodilator effect and the anabolic effect in rat, can be used for asthma research in athletes .
|
-
-
- HY-171242
-
|
|
JAK
STAT
|
Others
|
|
LNK01004 is a JAK inhibitor with strong inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50:＜0.51 nM) and TYK2 (IC50: 1.0 nM) . LNK01004 can simultaneously inhibit multiple cytokine-induced p-STAT signaling pathways. LNK01004 can be used in the research of diseases such as atopic dermatitis .
|
-
-
- HY-12887
-
-
-
- HY-B0629
-
|
|
Glucocorticoid Receptor
|
Metabolic Disease
Cancer
|
|
Mometasone is an inhaled glucocorticoid. Mometasone can be used in mild asthma with a low sputum eosinophil level. Mometasone has the potential for the research of chronic hand eczema and rhinosinusitis .
|
-
-
- HY-111346
-
-
-
- HY-111198
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
YM-355179 fumarate is a newly synthesized selective CCR3 antagonist with the potential to inhibit eosinophil-related allergic inflammatory diseases. YM-355179 can effectively inhibit the binding of CCL11 and CCL5 to CCR3-expressing cells, with IC50 values of 7.6 nM and 24 nM respectively. In functional experiments, YM-355179 can inhibit CCL11-induced intracellular Ca(2+) influx, chemotaxis and eosinophil degranulation, IC50 The values are 8.0 nM, 24 nM and 29 nM respectively .
|
-
-
- HY-W585843
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
1,1′-Ethylidenebis[L-tryptophan] is an impurity in the synthesis of L-tryptophan. 1,1′-Ethylidenebis[L-tryptophan] promotes the proliferation of eosinophilic leukemia cells, induces the release of eosinophil cationic protein from eosinophils, and stimulates T cells to produce IL-5. 1,1′-Ethylidenebis[L-tryptophan] (40 µg/kg) can induce fascia thickening, mast cell infiltration, and fibrosis in adipose and subcutaneous muscle tissues in mice. 1,1′-Ethylidenebis[L-tryptophan] can be used in immunology and inflammation research .
|
-
![1,1′-Ethylidenebis[L-tryptophan]](//file.medchemexpress.eu/product_pic/hy-w585843.gif)
-
- HY-P1764
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
Secretoneurin, rat, a 33-amino acid polypeptide, is generated by proteolytic processing of secretogranin II (SgII). Secretoneurin, rat induces dopamine release in the rat striatum in vivo and in vitro, and it exerts a very strong chemotactic effect on monocytes and eosinophils but not on granulocytes .
|
-
-
- HY-12887R
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
Cancer
|
|
Piclamilast (Standard) is the analytical standard of Piclamilast. This product is intended for research and analytical applications. Piclamilast (RP 73401) is a phosphodiesterase 4 (PDE4) inhibitor, with IC50 values of 16 nM and 2 nM in pig aorta and eosinophil soluble, respectively .
|
-
-
- HY-B0629R
-
|
|
Glucocorticoid Receptor
|
Metabolic Disease
|
|
Mometasone (Standard) is the analytical standard of Mometasone. This product is intended for research and analytical applications. Mometasone is an inhaled glucocorticoid. Mometasone can be used in mild asthma with a low sputum eosinophil level. Mometasone has the potential for the research of chronic hand eczema and rhinosinusitis .
|
-
-
- HY-112549
-
-
-
- HY-17042A
-
|
P071
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Cetirizine dihydrochloride, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine dihydrochloride marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
|
-
-
- HY-17042
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
|
-
-
- HY-N2297R
-
|
|
Antibiotic
|
Infection
|
|
Flunisolide (hemihydrate) (Standard) is the analytical standard of Flunisolide (hemihydrate). This product is intended for research and analytical applications. Flunisolide hemihydrate is a corticosteroid, which is an orally active glucocorticoid receptor activator with anti-inflammatory activity. Flunisolide hemihydrate can induce eosinophil apoptosis, and is used for the research of asthma or rhinitis, and inflammation .
|
-
-
- HY-100660A
-
|
|
Drug Metabolite
|
Others
|
|
Cetirizine Impurity B dihydrochloride is an impurity of Cetirizine dihydrochloride. Cetirizine, a second-generation antihistamine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
|
-
-
- HY-100661
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Cetirizine Impurity D is an impurity of Cetirizine. Cetirizine, a second-generation antihistamine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
|
-
-
- HY-120940A
-
|
|
PAK
|
Cancer
|
|
AZ13705339 hemihydrate is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 hemihydrate has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 hemihydrate can be used in the research of cancers .
|
-
-
- HY-120940
-
|
|
PAK
|
Cancer
|
|
AZ13705339 is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 can be used in the research of cancers .
|
-
-
- HY-17042AS
-
|
|
Isotope-Labeled Compounds
Histamine Receptor
|
Inflammation/Immunology
|
|
Cetirizine-d4 (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].
|
-
-
- HY-17042S
-
|
|
Histamine Receptor
|
Inflammation/Immunology
|
|
Cetirizine-d4 is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].
|
-
-
- HY-17042S1
-
|
|
Histamine Receptor
|
Inflammation/Immunology
|
|
Cetirizine-d8 is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].
|
-
-
- HY-P9923
-
|
MEDI-563; BIW-8405
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
|
-
-
- HY-17042AS1
-
|
|
Isotope-Labeled Compounds
Histamine Receptor
|
Inflammation/Immunology
|
|
Cetirizine-d8 (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].
|
-
-
- HY-17042R
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Cetirizine (Standard) is the analytical standard of Cetirizine. This product is intended for research and analytical applications. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
|
-
-
- HY-17042AR
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Cetirizine (dihydrochloride) (Standard) is the analytical standard of Cetirizine (dihydrochloride). This product is intended for research and analytical applications. Cetirizine dihydrochloride, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine dihydrochloride marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
|
-
- HY-11067
-
WHI-P97
2 Publications Verification
|
JAK
|
Inflammation/Immunology
|
|
WHI-P97 is a potent and selective JAK-3 inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo .
|
-
- HY-12284
-
|
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
NVP-QAV680 is a potent and selective CRTh2 receptor antagonist with low nanomolar (nM) functional potency to inhibit CRTh2-driven activation of human eosinophils and Th2 lymphocytes. NVP-QAV680 exhibits good oral bioavailability and demonstrates efficacy in CRTh2-dependent mechanisms and allergic disease models in rats .
|
-
- HY-100661R
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Cetirizine Impurity D (Standard) is the analytical standard of Cetirizine Impurity D. This product is intended for research and analytical applications. Cetirizine Impurity D is an impurity of Cetirizine. Cetirizine, a second-generation antihistamine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
|
-
- HY-106837
-
|
Y 24180
|
Platelet-activating Factor Receptor (PAFR)
|
Inflammation/Immunology
|
|
Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC50s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca 2+ influx and intracellular Ca 2+ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice .
|
-
- HY-105999B
-
-
- HY-134772
-
|
|
STAT
Cytochrome P450
|
Inflammation/Immunology
|
|
AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research .
|
-
- HY-13315
-
|
MK0476
|
Leukotriene Receptor
|
Inflammation/Immunology
Cancer
|
|
Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .
|
-
- HY-13315A
-
Montelukast
Maximum Cited Publications
9 Publications Verification
MK0476 free base
|
Leukotriene Receptor
|
Inflammation/Immunology
Cancer
|
|
Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .
|
-
- HY-116953
-
|
LXB4
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Lipoxin B4 (LXB4) is a structurally distinct product of arachidonic acid metabolism. Lipoxin B4 reduces leukocyte infiltration and mucus secretion in the nasal mucosa and decreases mast cell and eosinophil degranulation in the upper airway. Lipoxin B4 decreases airway inflammation, mucus metaplasia and hyper- responsiveness in the lower airway. Lipoxin B4 shows mucosal protective actions and has the potential for the research of allergic inflammation in the upper and lower airways .
|
-
- HY-15131
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
PNRI-299 is a selective AP-1 transcription inhibitor with an IC50 of 20 uM. PNRI-299 is a selective APE/Ref-1 inhibitor. PNRI-299 has no effect on NF-κB transcription or thioredoxin (up to 200 uM). PNRI-299 significantly reduces airway eosinophil infiltration, mucus hypersecretion, edema, and IL-4 levels in a mouse asthma model .
|
-
- HY-19472A
-
|
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
RWJ-58643 hydrochloride is a β-trypsin inhibitor that inhibits allergic inflammation. RWJ-58643 hydrochloride (100 mg) significantly reduces nasal allergy symptoms, eosinophil infiltration, and IL-5 levels at low doses. RWJ-58643 hydrochloride causes late eosinophilia and elevated IL-5 levels at high doses (300 mg and 600 mg). RWJ-58643 hydrochloride modulates allergic reactions by inhibiting the release of β-trypsin from mast cells.
|
-
- HY-19472
-
|
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
RWJ-58643 is a β-trypsin inhibitor that suppresses allergic inflammation. RWJ-58643 (100 mg) significantly reduced nasal allergy symptoms, eosinophil infiltration, and IL-5 levels at low doses. RWJ-58643 resulted in late eosinophilia and elevated IL-5 levels at high doses (300 mg and 600 mg). RWJ-58643 modulates allergic responses by inhibiting the release of β-trypsin from mast cells .
|
-
- HY-13315B
-
|
MK0476 dicyclohexylamine
|
Leukotriene Receptor
|
Inflammation/Immunology
Cancer
|
|
Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .
|
-
- HY-160998
-
|
|
CCR
|
Inflammation/Immunology
|
|
YM-344031 is an orally active antagonist for CCR3. YM-344031 inhibits binding of Eotaxin-1 and RANTES to CCR3, with IC50 of 3.0 and 16.3 nM. YM-344031 inhibits ligand-induced rise in intracellular Ca [2+] and the ligand-induced chemotaxis. YM-344031 inhibits eotaxin-1-induced changes in eosinophil morphology in macaques blood, and prevents allergic skin reactions in a mouse allergy model .
|
-
- HY-15342
-
|
OC000459
|
Prostaglandin Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Timapiprant (OC000459) is a potent, selective, and orally active D prostanoid receptor 2 (DP2, also known as CRTH2) antagonist. Timapiprant (OC000459) potently displaces [ 3H] PGD2 from human recombinant DP2 (Ki=13 nM), rat recombinant DP2 (Ki=3 nM), and human native DP2 (Ki=4 nM). Timapiprant (OC000459) inhibits mast cell activation of Th2 lymphocytes and eosinophils .
|
-
- HY-15342A
-
|
OC000459 sodium
|
Prostaglandin Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Timapiprant sodium (OC000459 sodium) is a potent, selective, and orally active D prostanoid receptor 2 (DP2, also known as CRTH2) antagonist. Timapiprant sodium (OC000459 sodium) potently displaces [ 3H] PGD2 from human recombinant DP2 (Ki=13 nM), rat recombinant DP2 (Ki=3 nM), and human native DP2 (Ki=4 nM). Timapiprant sodium (OC000459 sodium) inhibits mast cell activation of Th2 lymphocytes and eosinophils .
|
-
- HY-13315R
-
|
MK0476 (Standard)
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
Montelukast (sodium) (Standard) is the analytical standard of Montelukast (sodium). This product is intended for research and analytical applications. Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .
|
-
- HY-P9923A
-
|
MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )
|
Interleukin Related
|
Inflammation/Immunology
|
|
Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .
|
-
- HY-13315AR
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .
|
-
- HY-13315BR
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
Cancer
|
|
Montelukast (dicyclohexylamine) (Standard) is the analytical standard of Montelukast (dicyclohexylamine). This product is intended for research and analytical applications. Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .
|
-
- HY-109134A
-
|
TAS-205
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Pizuglanstat hydrate (TAS-205) is a hematopoietic prostaglandin D synthase (HPGDS) inhibitor. TAS-205 selectively inhibits the synthesis of prostaglandin D2 (PGD2) in cell-based enzymatic tests and in vivo models, and effectively reduces the entry of eosinophils into the nasal cavity and late-stage nasal congestion. When used in combination with montelukast (HY-13315A), TAS-205 showed a significant synergistic inhibitory effect; when used in combination with fexofenadine (HY-B0801A), it also had a certain inhibitory effect on early and late nasal congestion.
|
-
- HY-103363
-
|
|
CCR
Thymidylate Synthase
|
Inflammation/Immunology
Cancer
|
|
SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC50 of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006)-resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases .
|
-
- HY-B1639
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects .
|
-
- HY-110261
-
GS143
2 Publications Verification
|
IKK
E1/E2/E3 Enzyme
NF-κB
|
Inflammation/Immunology
|
|
GS143 is a selective IκBα ubiquitination inhibitor with an IC50 of 5.2 μM for SCF βTrCP1-mediated IκBα ubiquitylation. GS143 suppresses NF-κB activation and transcription of target genes and does not inhibit proteasome activity. GS143 has anti-asthma effect .
|
-
- HY-112621
-
|
LTA4 methyl ester
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Leukotriene A4 methyl ester (LTA4 methyl ester) is synthesized in mast cells, eosinophils, and neutrophils from arachidonic acid by 5-lipoxygenase (5-LO), which exhibits both lipoxygenase and LTA4 synthase activities. LTA4 is rapidly metabolized by LTA4 hydrolase or LTC4 synthase to LTB4 or LTC4, respectively. LTA4, from leukocytes, is known to undergo transcellular metabolism in platelets, erythrocytes, and endothelial cells. Further metabolism of LTA4 by 15-LO leads to lipoxin biosynthesis. LTA4 as a free acid is highly unstable. The methyl ester is stable and can be readily hydrolyzed to the free acid as needed.
|
-
- HY-115314
-
|
LG 30435
|
Histamine Receptor
|
Inflammation/Immunology
|
|
Mequitamium iodide (LG 30435) is an antihistamine drug with antiallergic and bronchodilatory activity. Mequitamium iodide can effectively antagonize airway contraction and inflammatory responses induced by histamine and antigens. Mequitamium iodide has nanomolar affinity for the H1 and smooth muscle receptors of histamine and mequitin. Mequitamium iodide, when administered in aerosol form, significantly inhibits histamine- and antigen-induced increases in airway pressure in allergic mice. Mequitamium iodide reduces antigen-induced eosinophil accumulation in the airways. Mequitamium iodide also exhibits inhibitory effects on PAF-induced platelet aggregation and bronchoconstriction, and can be used in the study of allergic diseases such as rhinitis and asthma .
|
-
- HY-N7801
-
|
|
Drug Isomer
|
Metabolic Disease
|
|
(±)5-HEPE is produced by non-enzymatic oxidation of EPA. It contains equal amounts of 5(S)-HEPE and 5(R)-HEPE. The biological activity of (±)5-HEPE is likely mediated by one of the individual isomers, most commonly the 5(S) isomer in mammalian systems. EPA can be metabolized to 5-HEPE in human and bovine neutrophils, and human eosinophils, which is further metabolized to 5-oxoEPE and LTB5. The 5-series metabolites of EPA, namely 5-HEPE, 5-oxoEPE, and LTB5, have significantly decreased biological effects compared to the arachidonic acid-derived metabolites.
|
-
- HY-107909
-
|
1,3-Dimethylxanthine sodium glycinate; Theo-24 sodium glycinate
|
Adenosine Receptor
HDAC
Apoptosis
Interleukin Related
TNF Receptor
|
Cancer
|
|
Theophylline (1,3-Dimethylxanthine) sodium glycinate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline sodium glycinate inhibits PDE3 activity to relax airway smooth muscle. Theophylline sodium glycinate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline sodium glycinate induces apoptosis. Theophylline sodium glycinate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
- HY-B0809S1
-
|
1,3-Dimethylxanthine-d3; Theo-24-d3
|
Endogenous Metabolite
Adenosine Receptor
HDAC
TNF Receptor
Interleukin Related
Phosphodiesterase (PDE)
Apoptosis
Isotope-Labeled Compounds
|
Cancer
|
|
Theophylline-d3 is deuterated labeled Theophylline (HY-B0809). Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
- HY-B0809A
-
|
1,3-Dimethylxanthine monohydrate; Theo-24 monohydrate
|
Phosphodiesterase (PDE)
Adenosine Receptor
HDAC
Apoptosis
Interleukin Related
TNF Receptor
Endogenous Metabolite
|
Cancer
|
|
Theophylline (1,3-Dimethylxanthine) monohydrate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) monohydrate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) monohydrate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) monohydrate induces apoptosis. Theophylline (1,3-Dimethylxanthine) monohydrate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
- HY-B0809
-
Theophylline
Maximum Cited Publications
9 Publications Verification
1,3-Dimethylxanthine; Theo-24
|
Phosphodiesterase (PDE)
Adenosine Receptor
HDAC
Apoptosis
Interleukin Related
TNF Receptor
Endogenous Metabolite
|
Cancer
|
|
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
- HY-B0809B
-
|
1,3-Dimethylxanthine sodium acetate; Theo-24 sodium acetate
|
Endogenous Metabolite
Phosphodiesterase (PDE)
Adenosine Receptor
HDAC
Apoptosis
Interleukin Related
TNF Receptor
|
Cancer
|
|
Theophylline (1,3-Dimethylxanthine) sodium acetate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) sodium acetate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) sodium acetate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) sodium acetate induces apoptosis. Theophylline (1,3-Dimethylxanthine) sodium acetate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
- HY-137863
-
|
|
Histamine Receptor
|
Inflammation/Immunology
|
|
Pemirolast is an orally active antiallergic agent. Pemirolast attenuates paclitaxel hypersensitivity reactions, can be used for bronchial asthma and conjunctivitis research - .
|
-
- HY-125782
-
|
15(R)-15-Methyl PGD2
|
Prostaglandin Receptor
|
Metabolic Disease
|
|
15(R)-15-Methyl prostaglandin D2 (15(R)-15-methyl PGD2) is a metabolically stable synthetic analog of PGD2. The physiological actions of PGD2 include regulation of sleep, lowering of body temperature, inhibition of platelet aggregation and relaxation of vascular smooth muscle. PGD2 mediates its effects by 2 distinct G-protein-coupled receptors, DP1and CRTH2/DP2. 15(R)-15-Methyl prostaglandin D2 is a potent, selective agonist for the CRTH2/DP2 receptor. The EC50 values for eosinophil CD11b expression, actin polymerization, and chemotaxis are 1.4, 3.8, and 1.7 nM, respectively, each of which is approximately 3-5 fold lower than those for PGD2. In contrast the EC50 for the DP1-mediated increase in platelet cAMP by 15(R)-15-methyl PGD2 is >10 μM.
|
-
- HY-101188
-
|
|
Histamine Receptor
|
Infection
|
|
INCB38579 is an orally active, highly brain penetrable, and selective histamine H4 receptor (HH4R) antagonist (hH4R IC50=4.8 nM, mH4R IC50=42 nM, rH4R IC50=32 nM). INCB38579 shows anti-inflammatory pain and anti-pruritic activities .
|
-
- HY-116028
-
|
15-Deoxy-Δ12,14-PGD2
|
Endogenous Metabolite
Prostaglandin Receptor
PPAR
Src
|
Cardiovascular Disease
|
|
15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2), a metabolite of PGD2 (HY-101988), is an agonist of prostaglandin receptor 2 (DP2). 15-deoxy-Δ12,14-Prostaglandin D2 binds to DP2 (Ki=50 nM) and induces eosinophil activation (EC50=8 nM). 15-deoxy-Δ12,14-Prostaglandin D2 also stimulates the recruitment of steroid receptor coactivator-1 (SRC-1) to peroxisome proliferator-activated receptor γ (PPARγ), inducing PPARγ-mediated transcription. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is cytotoxic to L1210 murine leukemia cells (IC50=0.3 μg/ml) and inhibits ADP-induced platelet aggregation (IC50=320 ng/mL).
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1764
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
Secretoneurin, rat, a 33-amino acid polypeptide, is generated by proteolytic processing of secretogranin II (SgII). Secretoneurin, rat induces dopamine release in the rat striatum in vivo and in vitro, and it exerts a very strong chemotactic effect on monocytes and eosinophils but not on granulocytes .
|
-
- HY-P4663
-
|
NSC 350591
|
Peptides
|
Cancer
|
|
Val-Gly-Ser-Glu (NSC 350591) is an ECF-A tetrapeptide. Val-Gly-Ser-Glu dose-dependently increases the number of human eosinophils, but not neutrophils, rosetting with complement-coated sheep erythrocytes (EAC3b) .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P990094
-
|
CSL311
|
c-Fms
|
Inflammation/Immunology
|
|
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research .
|
-
- HY-P99371
-
|
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
-
- HY-P9945
-
|
SB 240563
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
-
- HY-P9945A
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
-
- HY-P9923A
-
|
MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )
|
Interleukin Related
|
Inflammation/Immunology
|
|
Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .
|
-
- HY-P99846
-
|
QAX576
|
Interleukin Related
|
Inflammation/Immunology
|
|
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
|
-
- HY-P9923
-
|
MEDI-563; BIW-8405
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-17042S
-
|
|
|
Cetirizine-d4 is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].
|
-
-
- HY-17042S1
-
|
|
|
Cetirizine-d8 is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].
|
-
-
- HY-17042AS
-
|
|
|
Cetirizine-d4 (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].
|
-
-
- HY-17042AS1
-
|
|
|
Cetirizine-d8 (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].
|
-
-
- HY-B0809S1
-
|
|
|
Theophylline-d3 is deuterated labeled Theophylline (HY-B0809). Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![1,1′-Ethylidenebis[L-tryptophan]](http://file.medchemexpress.eu/product_pic/hy-w585843.gif)
